Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. More Details
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has Anika Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ANIK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ANIK's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: ANIK underperformed the US Biotechs industry which returned 20.3% over the past year.
Return vs Market: ANIK underperformed the US Market which returned 36.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Anika Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StAre Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?
2 months ago | Simply Wall StHave Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Been Selling Their Stock?
2 months ago | Simply Wall StDid You Miss Anika Therapeutics' (NASDAQ:ANIK) 22% Share Price Gain?
Is Anika Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ANIK ($40.28) is trading below our estimate of fair value ($92.13)
Significantly Below Fair Value: ANIK is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ANIK is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ANIK is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ANIK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ANIK is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (3x).
How is Anika Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ANIK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: ANIK is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ANIK's is expected to become profitable in the next 3 years.
Revenue vs Market: ANIK's revenue (14.2% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: ANIK's revenue (14.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ANIK's Return on Equity is forecast to be low in 3 years time (4.5%).
How has Anika Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ANIK is currently unprofitable.
Growing Profit Margin: ANIK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ANIK is unprofitable, and losses have increased over the past 5 years at a rate of 32.5% per year.
Accelerating Growth: Unable to compare ANIK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANIK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: ANIK has a negative Return on Equity (-9.74%), as it is currently unprofitable.
How is Anika Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ANIK's short term assets ($173.5M) exceed its short term liabilities ($47.0M).
Long Term Liabilities: ANIK's short term assets ($173.5M) exceed its long term liabilities ($38.6M).
Debt to Equity History and Analysis
Debt Level: ANIK is debt free.
Reducing Debt: ANIK had no debt 5 years ago.
Debt Coverage: ANIK has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ANIK has no debt, therefore coverage of interest payments is not a concern.
What is Anika Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ANIK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ANIK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ANIK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ANIK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ANIK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Cheryl Blanchard (57 yo)
Dr. Cheryl R. Blanchard, Ph.D. serves as the President & Chief Executive Officer of Anika Therapeutics, Inc. since April 26, 2020. She served as Interim Chief Executive Officer at Anika Therapeutics, Inc. ...
CEO Compensation Analysis
Compensation vs Market: Cheryl's total compensation ($USD10.10M) is above average for companies of similar size in the US market ($USD1.74M).
Compensation vs Earnings: Cheryl's compensation has increased whilst the company is unprofitable.
Experienced Management: ANIK's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Experienced Board: ANIK's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ANIK insiders have bought and sold the same number of shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Anika Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Anika Therapeutics, Inc.
- Ticker: ANIK
- Exchange: NasdaqGS
- Founded: 1983
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$579.680m
- Shares outstanding: 14.39m
- Website: https://www.anikatherapeutics.com
Number of Employees
- Anika Therapeutics, Inc.
- 32 Wiggins Avenue
- United States
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company’s joint pain management products inclu...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/24 01:54|
|End of Day Share Price||2021/07/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.